Profilnine, Profilnine HP, Profilnine HT, Profilnine SD Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of hemophilia diagnosis and care centers, availability of plasma-derived factor ix products, improved blood safety screening methods, growth of hospital-based hematology services, increasing awareness of bleeding disorder management.

The growth in the forecast period can be attributed to increasing adoption of long-term prophylactic therapies, rising investment in rare disease treatment access, expansion of home-based infusion models, growing focus on treatment safety and traceability, improvements in plasma supply chain resilience. Major trends in the forecast period include increasing demand for plasma-derived coagulation factors, expansion of hemophilia treatment programs, improved plasma fractionation and safety standards, rising use of prophylactic clotting factor therapy, enhanced focus on rare bleeding disorders.

The rise in the aging population is expected to drive the growth of the Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD market. The aging population is increasing due to higher life expectancy, declining birth rates, and advancements in healthcare that improve longevity. Profilnine products are used to manage bleeding disorders such as hemophilia B in older adults by providing clotting factor IX replacement therapy, reducing the risk of bleeding complications. For example, in January 2024, according to the Population Reference Bureau (PRB), a US-based nonprofit organization, the number of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, a 47% increase, with their share of the total population growing from 17% to 23%. Therefore, the rising aging population is driving the growth of the Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD market.

Rising prevalence of rare diseases is also expected to propel the market for Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD. Rare diseases affect a small portion of the population and often present unique diagnostic and treatment challenges. The growing incidence of rare diseases is driven by better diagnostic tools and increased awareness, enabling earlier detection of previously unrecognized conditions. Profilnine products help manage rare bleeding disorders by providing targeted plasma-derived clotting factor IX therapies that prevent and control bleeding episodes, improving patient outcomes and quality of life. For instance, in April 2025, according to Pfizer Inc., a US-based pharmaceutical company, the UK hemophilia A and B patient population exceeded 11,800 individuals during the 2023-2024 period, highlighting a clinically significant treated population. Therefore, the rising prevalence of rare diseases is driving the growth of this market.

The increase in healthcare expenditure is also expected to support the growth of the Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD market. Healthcare expenditure includes financial resources allocated to medical services, infrastructure, pharmaceuticals, and healthcare activities. Rising expenditure is driven by higher operational costs, increasing prevalence of chronic and lifestyle-related diseases, genetic disorders, medical technology advancements, and greater access to care. For Profilnine products, higher healthcare spending enhances access to clotting factor IX replacement therapies, improves patient outcomes, and reduces hospitalization costs. For example, in May 2024, according to the UK Office for National Statistics, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in 2022, while total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure is driving the growth of the Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD market.

Major companies operating in the profilnine, profilnine hp, profilnine ht, profilnine sd market are Grifols S.A.

North America was the largest region in the profilnine, profilnine HP, profilnine HT, profilnine SD market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the profilnine, profilnine hp, profilnine ht, profilnine sd market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the profilnine, profilnine hp, profilnine ht, profilnine sd market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the profilnine market by increasing costs of imported plasma fractionation equipment, sterile packaging components, cold-chain logistics systems, and quality testing technologies. North America and Europe are most affected due to dependence on international plasma sourcing and specialized manufacturing inputs. These tariffs are increasing therapy costs and placing pressure on healthcare budgets. At the same time, they are encouraging domestic plasma collection, regional manufacturing expansion, and strengthened local supply chains for critical coagulation factor therapies.

The profilnine, profilnine hp, profilnine ht, profilnine sd market research report is one of a series of new reports that provides profilnine, profilnine hp, profilnine ht, profilnine sd market statistics, including profilnine, profilnine hp, profilnine ht, profilnine sd industry global market size, regional shares, competitors with a profilnine, profilnine hp, profilnine ht, profilnine sd market share, detailed profilnine, profilnine hp, profilnine ht, profilnine sd market segments, market trends and opportunities, and any further data you may need to thrive in the profilnine, profilnine hp, profilnine ht, profilnine sd industry. This profilnine, profilnine hp, profilnine ht, profilnine sd market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Profilnine is a plasma-derived human coagulation factor IX concentrate used to treat and prevent bleeding in individuals with hemophilia B, a genetic disorder caused by a deficiency in factor IX that impairs blood clotting. Derived from human plasma, Profilnine temporarily raises factor IX levels, restoring clotting ability and helping manage bleeding episodes. It contains factor IX along with small amounts of other clotting factors, including II, VII, and X.

The primary indications for Profilnine, including Profilnine HP, Profilnine HT, and Profilnine SD, are hemophilia B, surgical procedures, and trauma management. Hemophilia B is a genetic condition in which insufficient factor IX leads to impaired clotting. Profilnine replenishes this clotting factor, reducing the risk of uncontrolled bleeding. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by hospitals, clinics, and home care settings.

The profilnine, profilnine HP, profilnine HT, profilnine SD market consist of sales of factor IX concentrate, administration kits, and dilution agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.